Article citationsMore >>

Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 2012; 52(6): 1213-25.

has been cited by the following article:

Article

Doxorubicin: Insights into Dynamics, Clinical Uses and Adverse Effects

1Pharm D, College of Pharmacy, Taif University, Taif, Saudi Arabia

2Pharmacology Department, Faculty of Medicine, Tanta University, Tanta, Egypt

3Department of Clinical Pharmacy, College of Pharmacy, Taif University, Taif, Saudi Arabia


Journal of Cancer Research and Treatment. 2019, Vol. 7 No. 1, 17-20
DOI: 10.12691/jcrt-7-1-3
Copyright © 2019 Science and Education Publishing

Cite this paper:
Amal A. Alghorabi, Ahmed M. Kabel, Maaly A. Abd Elmaaboud. Doxorubicin: Insights into Dynamics, Clinical Uses and Adverse Effects. Journal of Cancer Research and Treatment. 2019; 7(1):17-20. doi: 10.12691/jcrt-7-1-3.

Correspondence to: Ahmed  M. Kabel, Pharmacology Department, Faculty of Medicine, Tanta University, Tanta, Egypt. Email: ahmed.kabal@med.tanta.edu.eg

Abstract

Doxorubicin (DOX) is one of the anthracycline antibiotics that is used frequently for treatment of various types of malignancies including lung, breast and testicular cancers. DOX reacts with DNA by intercalation and inhibits the synthesis of DNA macromolecular components. Also, it may increase the production of free radicals which may contribute to its cytotoxicity. DOX may cause serious adverse effects including cardiotoxicity, hepatotoxicity and testicular toxicity. So, it has become increasingly important to find pharmacological remedies to protect against these serious adverse effects. This mini-review sheds light on DOX including its history, dynamics, clinical uses and adverse effects.

Keywords